XML 69 R57.htm IDEA: XBRL DOCUMENT v3.25.3
License Agreements - Lilly (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 190 Months Ended
Oct. 31, 2025
Dec. 31, 2009
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
License Agreements              
Total revenues     $ 1,365,980 $ 1,137,871 $ 3,634,407 $ 3,062,519  
Eli Lilly | Subsequent Event              
License Agreements              
Upfront payment received under license agreement $ 100,000            
Eli Lilly | OLUMIANT              
License Agreements              
Total revenues     $ 37,100 $ 34,800 $ 101,400 $ 97,100  
Development Milestones | Eli Lilly              
License Agreements              
Amount recognized and received for the achievement of a predefined milestone             $ 149,000
Development Milestones | Maximum | Eli Lilly              
License Agreements              
Upfront and immediate milestone payment to be received under license agreement   $ 150,000          
Regulatory Milestones | Eli Lilly              
License Agreements              
Amount recognized and received for the achievement of a predefined milestone             335,000
Regulatory Milestones | Maximum | Eli Lilly              
License Agreements              
Upfront and immediate milestone payment to be received under license agreement   365,000          
Commercialization Milestones | Eli Lilly              
License Agreements              
Amount recognized and received for the achievement of a predefined milestone             $ 50,000
Commercialization Milestones | Maximum | Eli Lilly              
License Agreements              
Upfront and immediate milestone payment to be received under license agreement   $ 150,000